Provided by Tiger Fintech (Singapore) Pte. Ltd.

Xencor

10.65
+0.05000.47%
Post-market: 10.650.00000.00%16:30 EDT
Volume:811.14K
Turnover:8.51M
Market Cap:750.42M
PE:-2.98
High:10.81
Open:10.73
Low:10.20
Close:10.60
Loading ...

Xencor Q4 EPS $(0.62) Beats $(0.78) Estimate, Sales $52.79M Beat $19.48M Estimate

Benzinga
·
27 Feb

Earnings Flash (XNCR) Xencor Posts Q4 Net Loss $0.62 a Share, vs. FactSet Est of $0.78 Loss

MT Newswires Live
·
27 Feb

BRIEF-Xencor Q4 Net Income USD -46.199 Million

Reuters
·
27 Feb

Xencor Inc - Expects to End 2025 With $535M-$585M in Cash and Equivalents

THOMSON REUTERS
·
27 Feb

Xencor Q4 Operating Expenses USD 65.972 Million

THOMSON REUTERS
·
27 Feb

Xencor Inc - Financial Statements for Certain Years Are Not to Be Relied Upon

THOMSON REUTERS
·
13 Feb

Xencor Inc Says Determined to Restate Affected Financial Statements to Address Foregoing and Will Prepare Amendments to Each of Prior Filings

THOMSON REUTERS
·
13 Feb

Xencor Inc - Restatement of Affected Financial Statements Not Anticipated to Have Material Impact on Co's Future Business or Operations

THOMSON REUTERS
·
13 Feb

Xencor (XNCR) Loses -25.22% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks
·
06 Feb

Xencor (NASDAQ:XNCR investor five-year losses grow to 50% as the stock sheds US$96m this past week

Simply Wall St.
·
01 Feb

After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor (XNCR)

Zacks
·
20 Jan

Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 Weeks

Zacks
·
15 Jan

Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know

Zacks
·
15 Jan

Analysts Conflicted on These Healthcare Names: Xencor (XNCR) and Pfizer (PFE)

TIPRANKS
·
14 Jan

Bank of America Securities Remains a Buy on Xencor (XNCR)

TIPRANKS
·
14 Jan

Xencor Inc : Raymond James Adds Stock to Its Analyst Current Favorites List

THOMSON REUTERS
·
18 Dec 2024

All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy

Zacks
·
13 Dec 2024

Wells Fargo Initiates Xencor at Overweight With $37 Price Target

MT Newswires Live
·
12 Dec 2024

Promising Prospects for Xencor’s Plamotamab in Autoimmune Treatments Drive Buy Rating

TIPRANKS
·
10 Dec 2024

Piper Sandler Upgrades Xencor to Overweight, Price Target is $30

MT Newswires Live
·
02 Dec 2024